invoX Pharma and F-star Therapeutics Inc. entered into a definitive agreement whereby invoX will acquire all of the issued and outstanding shares of F-star common stock for $7.12 per share. The proposed acquisition values F-star at approximately $161 million. PJT Partners Inc. is acting as financial advisor to invoX.